Healthcare, Pharma & Biotech

Dr. Jing Ma joined Jefferies in June 2025 as a research analyst specializing in China biotech. Jing brings extensive experience in the biotechnology industry as well as venture capitals. Prior to joining Jefferies, Jing worked as Healthcare Investment Director at Vertex Ventures, and Beijing Grains Valley Venture Capital. Before that, Jing also worked for Wuxi

David Shang joined Jefferies in Oct 2024, as a research analyst in China healthcare team. He has rich experience in China healthcare space for 9 years. Previously he worked at Barings Asset Management as healthcare analyst. Prior to that, he was at Citigroup, where he was a member of the II Asia No.1 ranking healthcare

Chu Wang joined Jefferies in Sep 2024, as a research analyst in China Healthcare team. Previously, he worked for Citigroup Research for 3 years, where he was a member of the II Asia No.1 ranking team in healthcare. Prior to that, he was a FICC trader in CDB. He comes with degrees of Bachelor of

Cui Cui is Jefferies Head of Asia Healthcare. She ranked No.1 in 2025 Extel(II) Asia Healthcare during her first year at Jefferies, securing first-ever No.1 team ranking for Jefferies Asia. Cui comes with rich experience in healthcare for 12 years in UBS AM and Citigroup as Head of China Healthcare (No.1 in II Asia Healthcare

What I am Known For How I am Different Key Research Highlights

David Stanton joined Jefferies Australia in September 2019. Prior to joining the company David worked for ABN Amro/RBS, Nomura and CLSA in Sydney. David is a Doctor of Medicine and holds an MBA from the Australian Graduate School of Management. Vanessa Thomson Vanessa Thomson joined Jefferies Australia in September 2019 from CLSA Australia. Before this

Alok Dalal joined Jefferies in December of 2022, following 14 years as a senior analyst covering the Indian Healthcare sector at CLSA India, Motilal Oswal and BNP Paribas. Alok began his equity research career in 2005, and has covered telecom, aviation and healthcare sectors. Alok has been ranked in Institutional Investor and Asia Money for

Dhawal is member of Jefferies India Healthcare team since 2020 and currently leads coverage of India-based CRDMO stocks. Prior to Jefferies he worked for couple of years with HSBC equity research and Credit Suisse as a software developer. Dhawal has a total of seven years of work experience in equity research. He completed his Bachelor